1423 related articles for article (PubMed ID: 7076797)
1. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
2. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
[TBL] [Abstract][Full Text] [Related]
3. Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia.
Packard CJ; Stewart JM; Third JL; Morgan HG; Lawrie TD; Shepherd J
Biochim Biophys Acta; 1980 Apr; 618(1):53-62. PubMed ID: 6990991
[No Abstract] [Full Text] [Related]
4. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
[TBL] [Abstract][Full Text] [Related]
5. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
Gavish D; Oschry Y; Fainaru M; Eisenberg S
Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
7. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
[TBL] [Abstract][Full Text] [Related]
8. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
Artery; 1985; 12(6):363-81. PubMed ID: 4051756
[TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
[TBL] [Abstract][Full Text] [Related]
10. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia.
Brunzell JD; Albers JJ; Chait A; Grundy SM; Groszek E; McDonald GB
J Lipid Res; 1983 Feb; 24(2):147-55. PubMed ID: 6403642
[TBL] [Abstract][Full Text] [Related]
11. [Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(12):1682-4. PubMed ID: 6686774
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
[TBL] [Abstract][Full Text] [Related]
13. [Quantitative analysis of lipoproteins in hyperlipoproteinemias of type IIa, IIb and IV (author's transl)].
Loeper J; Goy-Loeper J; Rouffy J
Clin Chim Acta; 1979 Oct; 98(1-2):19-26. PubMed ID: 227624
[TBL] [Abstract][Full Text] [Related]
14. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
Oida K; Nakai T; Tamai T; Kutsumi Y; Kobayashi T; Hayashi T; Yamada S; Takeda R
Artery; 1982; 10(4):266-85. PubMed ID: 7181672
[TBL] [Abstract][Full Text] [Related]
15. Plasma lipoprotein levels and the prevalence of hyperlipoproteinemia in a Canadian working population.
Jones GJ; Hewitt D; Godin GJ; Breckenridge WC; Bird J; Mishkel MA; Steiner G; Little JA
Can Med Assoc J; 1980 Jan; 122(1):37-8, 40-6. PubMed ID: 7363194
[TBL] [Abstract][Full Text] [Related]
16. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
Hutt V; Klör HU; Wechsler JG; Ditschuneit H
J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
[TBL] [Abstract][Full Text] [Related]
17. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Artery; 1980; 8(2):113-9. PubMed ID: 7458676
[TBL] [Abstract][Full Text] [Related]
18. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.
Eisenberg S; Gavish D; Oschry Y; Fainaru M; Deckelbaum RJ
J Clin Invest; 1984 Aug; 74(2):470-82. PubMed ID: 6378975
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
20. [The relationship of cholesterol (CHO) and triglycerides (TG) in VLDL, LDL, and VLDL subfractions by agarose gel electrophoresis, using CHO and TG dual staining (AG-CHO, TG staining)].
Miyake N; Iizuka K
Rinsho Byori; 2002 Jun; 50(6):605-12. PubMed ID: 12166081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
